ADHD medicines – phased return to routine prescribing
Following improvements in the national supply position, ADHD medicines are no longer considered to be in sustained shortage. As a result, prescribing of 12‑hour modified-release methylphenidate is now moving through a phased (non-blanket) return to brand prescribing, in line with local ADHD shared care protocols and national medicine safety guidance.
Further detail, including formulation- and product-specific requirements, and a list of medicines that must always be prescribed by brand, is provided in the ADHD Medicines Shortages – Post Supply Recovery Guidance.
ADHD
